Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 6/20 | 0.38 |
| ▸ | USP2 | O75604 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106738 | 1.00 | TACR2 (0.38) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3985800 | 0.91 | TACR2 (0.36) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3985802 | 0.91 | TACR2 (0.36) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3979699 | 0.91 | TACR2 (0.42) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3979429 | 0.91 | RHOC (0.39) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3979427 | 0.91 | RHOC (0.39) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3979698 | 0.91 | TACR2 (0.42) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL4631148 | 0.90 | TACR2 (0.46) | TACR2USP2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL6662514 | 0.89 | KMT2A (0.39) | TACR2TACR1 | |
| SCHEMBL5106731 | 0.89 | TACR2 (0.39) | TACR2USP2CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | TACR2 360/4885USP2 3612/4885CYP3A4 36/4885 |
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | TACR2 3/4885USP2 4432/4885CYP3A4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.